Stock ACAD ACADIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
17.19 USD +0.64% Intraday chart for ACADIA Pharmaceuticals Inc. -3.05% -45.10%
Apr. 17 ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting CI
Apr. 02 ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
BU
ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting
CI
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
BU
ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
CI
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing
MT
JPMorgan Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $29, Maintains Overweight Rating
MT
Transcript : ACADIA Pharmaceuticals Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 02:00 PM
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 15, 2024
AQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
BU
UBS Adjusts ACADIA Pharmaceuticals Price Target to $33 From $35, Maintains Buy Rating
MT
Morgan Stanley Cuts Price Target on ACADIA Pharmaceuticals to $30 From $40 After Failed Study of Pimavanserin in Negative Symptoms of Schizophrenia; Overweight Kept
MT
North American Morning Briefing : Stock Futures -2-
DJ
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $22 From $24, Maintains Hold Rating
MT
Cantor Fitzgerald Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $42, Maintains Overweight Rating
MT
Sector Update: Health Care Stocks Gain Premarket Tuesday
MT
Baird Adjusts Price Target on ACADIA Pharmaceuticals to $31 From $40, Maintains Outperform Rating
MT
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell
MT
Needham Lowers Price Target on ACADIA Pharmaceuticals to $32 From $36, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACAD Stock
  4. News ACADIA Pharmaceuticals Inc.